Inside the PSA Japan Weekly Research Round-Up you have:
The Weekly Comment by Pelham Smithers (available upon request):
Eagerly awaiting the Q4 GDP figures…
Reports / Flash Notes Published This Week: Headlines at a Glance (full reports available upon request):
1. Japanese Pharma Strategy
Company / Sector / Thematic Comments at a Glance (for more details, please ask):
Technology:
1. Sony (6758): Shows Interest in Fox Assets
2. Comparing General Electric with Hitachi
3. iPhone X Battery / New Models
4. Canon (7751): Confirmation of Commemoration
Chemicals / Electronic Materials
5. Sumitomo Bakelite (4203): Conservative Guidance
6. Showa Denko (4004): Strong Q3 but SGL Remains an Unknown Factor in Q4
7. Shin-Etsu (4063): Continues to Enjoy Strong Business Conditions
8. China’s YMTC Reportedly Making Faster Progress on 3D NAND, but it May Not Matter
9. Fujifilm Holdings (4901): Remains Ahead of Target Despite the One-time Fuji Xerox Costs
Autos
10. Is the India Auto Sales Rally Coming to an End?
11. Will China’s New Trade Policies Help Japanese Automakers?
12. European Auto Market: In Good Shape, but Concerns Over Brexit Trade Negotiations Raised
13. NAFTA: Toyota’s Production Plans for Mexico Could be a Risky Bet
Auto Parts / Machinery
14. Daifuku (6383): Lead-Times and Cautionary Comments / Added to MSCI Japan Index
15. Ryosan (8140): Echoing Daifuku’s Caution of Froth at the Top
16. Daikin (6367): Confident in Future Price Hikes to Offset Higher Raw Material Costs
17. Ferrotec (6890): Solar Hopes Shining Brighter
18. Ebara (6361): Excellent Q2
19. Mitsubishi Electric (6503): China Production Base Expansion
20. KHI (7012): Threats and Opportunities
Internet
21. Nexon (3659): Impressive Q3 Results Masks Earnings Volatility
22. Rakuten (4755): Our Neutral Stance Remains
23. Recruit Holdings (6098): Rich Valuations and Concerns on Earnings Volatility
24. Avex (7860): Weak H1 Suggests a Challenge to Meet FY Targets
25. Trend Micro (4704): Continues to Trend Upwards
Pharma:
26. Pharma Strategy: What’s in the Pipeline and What’s in the Price
27. US FDA Approves Chugai's Hemlibra (ACE910 / emicizumab) for Haemophilia A
Media:
28. WPP Offers / Threatens to raise its stake in Asatsu
PSA Company Visits, Tours and Interviews:
• Participated in the earnings call of Showa Denko (4004)
• Earnings meetings: Sumitomo Bakelite (4203), Sumitomo Metal Mining (5713), Fujimori Kogyo (7917), Fujimi Corporation (5384), Soken Chemical (4972), Mitsui Chemicals (4183), Japan
Elevator Services (6544), Credit Saison (8253), Daifuku (6383), Medinet (2370), Showa Sangyo (2004), Aozora Bank (8304), Unipress (5949), Fuji Oil (5017)
• Visited Shin-Etsu Chemical (4063), Asahi Kasei (3407), Tokyo Ohka Kogyo (4186), Hitachi Chemical (4217), Japan Display (6740), Teijin (3401), Fujifilm Holdings (4901), Kuraray (3405)
• Watched earnings webcast of Rakuten (4755)
• Had a conference call with Daikin (6367)
PSA In the Media
Pelham Smithers is quoted in the FT Lex Column discussing FAANGs (https://www.ft.com/content/49716e50-c61d-11e7-a1d2-6786f39ef675) [Paywall]
List of PSA Published Reports since July 2017:
Founded in 2009, Pelham Smithers Associates (PSA) provides market intelligence on Asian technology, focusing in particular on Japan. The industries covered by our team of specialists are: consumer electronics, telecomms, pharmaceuticals, internet, electronic parts and materials, automotive technology, retail and capital goods.
PSA produces both company and sector reports. The focus of PSA’s research is to identify winners and losers as new technologies impact the top and bottom lines of corporations. Critical to our research is the clear explanation of how these new technologies work and how they impact companies and industries.
The founding partners have worked closely together for twenty years and the team has more than doubled in size since 2012.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.